Nemotan (Nimodipine)

Nimodipine selectively blocks L‑type calcium channels in the smooth muscle of cerebral arteries. This blockade causes the vessels to relax, leading to vasodilation and improved cerebral perfusion, which counteracts the narrowing that can follow a subarachnoid hemorrhage.

The dosage of Nemotan is determined by the prescribing clinician based on the patient’s clinical condition, age, weight, and renal or hepatic function. Healthcare professionals follow established guidelines and adjust the regimen as needed for each individual.

Safety data for nimodipine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Nemotan product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nimodipine is the most widely studied calcium‑channel blocker for this indication and is preferred because of its selective action on cerebral vessels. Other agents, such as non‑selective vasodilators, may lack the same level of evidence for improving neurological outcomes after subarachnoid hemorrhage.

Nemotan should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity.

Nemotan is taken orally, usually as a tablet, with or without food as directed by the prescriber. The medication should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

The most serious adverse events include severe hypotension, syncope, cardiac arrhythmias, and rare cases of hepatic dysfunction. Patients should be monitored for signs of low blood pressure, dizziness, or any unexpected cardiac symptoms, and medical attention should be sought promptly if they occur.

Nemotan is contraindicated in patients with known hypersensitivity to nimodipine or any other dihydropyridine calcium‑channel blockers. Caution is also advised for individuals with severe hypotension, uncontrolled heart failure, or significant liver impairment, where the risks may outweigh the benefits.